From the Research
BPC-157 is an experimental peptide that should not be used without medical supervision due to limited research on its safety and efficacy in humans, and its use should be prioritized based on the most recent and highest quality study available, which is the 2021 study published in Frontiers in Pharmacology 1. BPC-157 is a synthetic peptide derived from a protein found in human gastric juice, and it has been studied primarily in animal models for potential tissue healing and anti-inflammatory effects. Some proposed applications include healing of tendons, ligaments, muscles, and gastrointestinal tissues.
- Typical experimental protocols use doses ranging from 200-500 mcg per day, often administered via subcutaneous injection or oral consumption.
- Treatment durations in studies have varied widely from a few days to several weeks.
- While some athletes and bodybuilders have used BPC-157 for injury recovery, its use carries significant risks, including potential side effects and long-term safety concerns, as well as possible interactions with other medications or effects on hormone levels. The peptide's mechanism of action is thought to involve modulation of growth factors and angiogenesis (formation of new blood vessels), as suggested by the 2021 study published in Frontiers in Pharmacology 1, which found that BPC-157 has practical applicability in wound healing and may prevent and/or attenuate or eliminate thrombosis. Given its experimental nature, individuals should not self-administer BPC-157, and any use should occur only under close medical supervision as part of an approved clinical trial or treatment protocol, as recommended by the 2019 study published in Cell and Tissue Research 2. Safer, proven alternatives for tissue healing and injury recovery should be pursued first.
- The most recent and highest quality study available, which is the 2021 study published in Frontiers in Pharmacology 1, should be prioritized when considering the use of BPC-157.
- The 2018 study published in Current Pharmaceutical Design 3 and the 2018 study published in Current Pharmaceutical Design 4 provide additional information on the potential benefits and mechanisms of BPC-157, but the 2021 study published in Frontiers in Pharmacology 1 is the most recent and highest quality study available.
- The 2021 study published in Alternative Therapies in Health and Medicine 5 and the 2019 study published in Cell and Tissue Research 2 also provide valuable information on the potential benefits and risks of BPC-157, but the 2021 study published in Frontiers in Pharmacology 1 is the most relevant and reliable source of information.